Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 29 January 2025
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC